Neutrophil counts in persons of African origin

aHIV Pathogenesis Programme, Doris Duke Medical Research Institute bKwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa cRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, Massachusetts, USA dMax Planck Institute for Infection Biology, Berlin, Germany.
Current opinion in hematology (Impact Factor: 3.97). 11/2013; 21(1). DOI: 10.1097/MOH.0000000000000007
Source: PubMed


The causes of ethnic or benign neutropenia have long been unclear. Here, we discuss the emerging data on the causes and consequences of neutropenia and discuss the relevance of these data for African populations, in which the prevalence of neutropenia is high.
Genetic deletion of the Duffy antigen receptor for chemokines (DARC-null genotype) has been identified as a major determinant for neutropenia. DARC acts as a receptor for Plasmodium vivax malaria and the DARC-null genotype has thus been positively selected among Africans; however, recent studies suggest that Duffy-null-linked neutropenia could increase the risk of HIV infection. Data are emerging that neutrophils are versatile cells that play a critical role not only in direct antimicrobial activity but also in priming and regulating the activity of other innate and adaptive immune cells. Therefore, we discuss here the imperative to better understand the causes, consequences, and the underlying mechanisms of neutropenia among Africans as a prerequisite for rational and optimal biomedical interventions to improve health outcomes.
Neutropenia among Africans, linked to the Duffy-null trait or otherwise, may have significant health consequences that remain largely undetermined and could have a significant impact on the pathogenesis of diseases.

116 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Une neutropénie se définit comme une diminution du taux de polynucléaires neutrophiles en dessous de 1,5 G/L. Elle est considérée comme légère entre 1,5 et 1 G/L, modérée entre 1 et 0,5 G/L et sévère en dessous de 0,5 G/L. Son principal risque est d’ordre infectieux, d’autant plus que la neutropénie est profonde et prolongée. Elle nécessite un bilan étiologique exhaustif afin d’adapter la prise en charge thérapeutique. En pratique rhumatologique, les neutropénies constitutionnelles sont rares : elles s’observent chez les patients d’origine africaine et sont en général modérées et bénignes. Les formes congénitales liées à des anomalies génétiques sont graves et essentiellement observées en pédiatrie. Au cours de la polyarthrite rhumatoïde, les neutropénies sont majoritairement acquises. L’étiologie médicamenteuse est la plus fréquente et justifie un interrogatoire rigoureux. De nombreux médicaments utilisés dans cette pathologie sont susceptibles d’induire une neutropénie. La carence en folates doit systématiquement être recherchée en cas de prise de méthotrexate. Plus rarement, la neutropénie est d’origine auto-immune, secondaire à la polyarthrite rhumatoïde. La présence d’une splénomégalie suggère un syndrome de Felty qui peut être associé dans 40 % des cas à une leucémie à lymphocytes granuleux. La prise en charge thérapeutique est conditionnée par la profondeur de la neutropénie et le bilan étiologique. Une neutropénie inférieure à 0,5 G/L, une fièvre et l’existence de signes cliniques constituent des facteurs de gravité impliquant une prise en charge urgente, le risque vital étant engagé. Dans les autres situations, l’arrêt de toute prise médicamenteuse suspecte doit être envisagé en premier lieu conjointement à la réalisation du bilan étiologique.
    Revue du Rhumatisme 01/2015; 82(2). DOI:10.1016/j.rhum.2014.12.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neutropenia is defined as a neutrophil count lower than 1.5g/L, with categorization as mild, moderate, or severe when the count is 1.5-1g/L, 1-0.5g/L, or<0.5g/L, respectively. The main complication is infection, whose risk increases with the depth and duration of the neutropenia. Comprehensive etiological investigations are mandatory to determine the best treatment strategy. Constitutional neutropenia is rarely seen in everyday rheumatology practice. It predominantly affects patients of African descent and is usually moderate and well tolerated. Congenital neutropenia due to genetic abnormalities is severe and chiefly seen in the pediatric population. Most cases of neutropenia in patients with rheumatoid arthritis (RA) are acquired. Medications are the most common causes, making detailed history-taking crucial. Many medications used to treat RA can induce neutropenia. Folic acid deficiency should be sought routinely in patients taking methotrexate. A less common cause of neutropenia is an RA-related autoimmune reaction. Splenomegaly suggests Felty's syndrome, which is accompanied with large granular lymphocytic (LGL) leukemia in 40% of cases. The treatment depends on the depth of the neutropenia and findings from the etiological workup. A neutrophil count below 0.5g/L, a fever, and the presence of clinical signs indicate a life-threatening condition requiring emergent treatment. In other patients, the first step is immediate discontinuation of any possibly involved drugs, simultaneously with the etiological workup. Copyright © 2015 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
    Joint, bone, spine: revue du rhumatisme 03/2015; 82(4). DOI:10.1016/j.jbspin.2015.01.005 · 2.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 37 million individuals are currently infected with Onchocerca volvulus (O. volvulus), a parasitic nematode that elicits various dermal manifestations and eye damage in man. Disease control is primarily based on distributing ivermectin in mass drug administration (MDA) programmes which aim at breaking transmission by eliminating microfilariae (MF), the worm's offspring. The majority of infected individuals present generalized onchocerciasis, which is characterized by hyporesponsive immune responses and high parasite burden including MF. Recently, in areas that have been part of MDA programmes, individuals have been identified that present nodules but are amicrofilaridermic (a-MF) and our previous study showed that this group has a distinct immune profile. Expanding on those findings we determined the immune responses of O. volvulus-infected individuals to a Plasmodium-derived antigen MSP-1 (merozoite surface protein-1), which is required by the parasite to enter erythrocytes. Isolated PBMCs from O. volvulus-infected individuals (164 MF+ and 46 a-MF) and non-infected volunteers from the same region (NEN), were stimulated with MSP-1 and the resulting supernatant screened for the presence of IL-5, IL-13, IFN-γ, TNF-α, IL-6, IL-17A and IL-10. These findings were then further analyzed following regression analysis using the covariates MF, ivermectin (IVM) and region. The latter referred to the Central or Ashanti regions of Ghana, which, at the time sampling, had received 8 or 1 round of MDA respectively. IL-5, IL-13 and IFN-γ responses to MSP-1 were not altered between NEN and O. volvulus-infected individuals nor were any associations revealed in the regression analysis. IL-10, IL-6 and TNF-α MSP-1 responses were, however, significantly elevated in cultures from infected individuals. Interestingly, when compared to a-MF individuals, MSP-induced IL-17A responses were significantly higher in MF+ patients. Following multivariable regression analysis these IL-10, IL-6, TNF-α and IL-17A responses were all dominantly associated with the regional covariate. Consequently, areas with a lowered infection pressure due to IVM MDA appear to influence bystander responses to Plasmodium-derived antigens in community members even if they have not regularly participated in the therapy.
    Parasites & Vectors 03/2015; 8(1). DOI:10.1186/s13071-015-0786-5 · 3.43 Impact Factor
Show more